Respiratory syncytial virus infection: therapy and prevention (Q35674160)

9 August 2017

1 reference

title

Respiratory syncytial virus infection: therapy and prevention (English)

1 reference

9 August 2017

Robert C Welliver

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Paediatric Respiratory Reviews

9 August 2017

published in

1 reference

9 August 2017

volume

5 Suppl A

1 reference

9 August 2017

page(s)

S127-33

1 reference

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Pathological changes in virus infections of the lower respiratory tract in children

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Randomized trial of salbutamol in acute bronchiolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

The effect of nebulized epinephrine on respiratory mechanics and gas exchange in bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

The use of albuterol in hospitalized infants with bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Efficacy of beta 2-Agonists in Bronchiolitis: A Reappraisal and Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Oral versus nebulized albuterol in the management of bronchiolitis in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Effect of salbutamol on oxygen saturation in bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Dexamethasone in bronchiolitis: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Efficacy of oral dexamethasone in outpatients with acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Vitamin A therapy for children with respiratory syncytial virus infection: a multicenter trial in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Vitamin A and respiratory syncytial virus infection. Serum levels and supplementation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Surfactant protein levels in severe respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

The compound DATEM inhibits respiratory syncytial virus fusion activity with epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Novel anti-respiratory syncytial(RS) viral compounds: benzodithiin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Heliox therapy in infants with acute bronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Maternal immunization against viral disease

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Protection against respiratory syncytial virus infection by DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Evaluation of Two Live, Cold‐Passaged, Temperature‐Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and Children

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Protective Immune Responses Induced by the Immunization of Mice with a Recombinant Bacteriophage Displaying an Epitope of the Human Respiratory Syncytial Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1526-0542%2804%2990024-3

7 January 2021

10.1016/S1526-0542(04)90024-3

Identifiers

DOI

1 reference

9 August 2017

1 reference